Pre-clinical trial stem cell metabolites derived from placenta for wound healing

Previous research focuses on in vitro study of stem cell metabolites derived from placenta for wound healing. This study, however, is an advanced stage which focuses on testing the efficiency and efficacy of stem cell metabolites in rats (Rattus novergicus). The tests carried out examined the blood levels with ELISA instruments and integument histology by observing the activity of polymorph nuclear and monocyte cells in the control and treatment groups. In the control group, the rats were injured in the anterior and posterior back skin with a 1 × 1 cm incision wound, (only antibiotics), while the treatment group uses antibiotics and 4 mL injections of stem cell metabolites. Each group was repeated three times with the samples observed for blood levels using ELISA Interleukin-4, Interleukin-10 and Tumor Necrosis Factor-α, with integument histology at pre-injection, in days 1, 3 and 6. These were used to compare the development of inflammatory cells, polymorphonuclear and monocytes between the control and treatment groups. Stem cell metabolites are significantly effective and efficient with the ability to inhibit the inflammatory process in tissues in terms of examining the blood levels of rats using ELISA Interleukin-4, Interleukin-10 and Tumor Necrosis Factor-α. Interleukin-4 and Interleukin-10 (anti-inflammatory) tend to significantly increase the treatment group, while Tumor Necrosis Factor-α (pro-inflammation) increases the control group. Histology results showed a decrease in the activity of polymorphonuclear and monocytes inflammatory cells in the treatment group compared to the control, which indicated that the stem cell metabolites were able to significantly inhibit the inflammatory process. It is concluded that stem cell metabolites derived from placenta are effective and efficient for wound healing in rats. Clinical study is needed for further research for it to be used on humans.